Header Logo

Connection

Theo Manschreck to Antipsychotic Agents

This is a "connection" page, showing publications Theo Manschreck has written about Antipsychotic Agents.
Connection Strength

2.433
  1. Boshes RA, Manschreck TC. Less is more Redux: Scheduled intermittent dosing to protect/prevent cognitive deterioration in schizophrenia. Med Hypotheses. 2016 May; 90:79-81.
    View in: PubMed
    Score: 0.508
  2. Osser DN, Roudsari MJ, Manschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013 Jan-Feb; 21(1):18-40.
    View in: PubMed
    Score: 0.406
  3. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007 Sep-Oct; 15(5):245-58.
    View in: PubMed
    Score: 0.281
  4. Manschreck TC, Khan NL. Recent advances in the treatment of delusional disorder. Can J Psychiatry. 2006 Feb; 51(2):114-9.
    View in: PubMed
    Score: 0.251
  5. Boshes RA, Manschreck TC. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr Bull. 2002; 28(2):203-22.
    View in: PubMed
    Score: 0.189
  6. Manschreck TC, Redmond DA, Candela SF, Maher BA. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci. 1999; 11(4):481-9.
    View in: PubMed
    Score: 0.154
  7. Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. Psychiatr Serv. 2016 12 01; 67(12):1370-1372.
    View in: PubMed
    Score: 0.130
  8. Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015 Mar; 41(2):449-59.
    View in: PubMed
    Score: 0.112
  9. Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, Buckley P, Manschreck TC, Achtyes ED, Macklin EA. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol. 2013 Aug; 33(4):485-90.
    View in: PubMed
    Score: 0.106
  10. Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA. Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophr Res. 2011 Aug; 130(1-3):47-52.
    View in: PubMed
    Score: 0.091
  11. Boshes RA, Manschreck TC, Desrosiers J, Candela S, Hanrahan-Boshes M. Initiation of clozapine therapy in a patient with preexisting leukopenia: a discussion of the rationale of current treatment options. Ann Clin Psychiatry. 2001 Dec; 13(4):233-7.
    View in: PubMed
    Score: 0.047
  12. Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, Buckley PF. Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? Schizophr Res. 2018 03; 193:263-268.
    View in: PubMed
    Score: 0.035
  13. Manschreck TC. Delusional disorder: the recognition and management of paranoia. J Clin Psychiatry. 1996; 57 Suppl 3:32-8; discussion 49.
    View in: PubMed
    Score: 0.031
  14. Manschreck TC, Maher BA, Rosenthal JE, Berner J. Reduced primacy and related features in schizophrenia. Schizophr Res. 1991 Jul-Aug; 5(1):35-41.
    View in: PubMed
    Score: 0.023
  15. Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb; 33(3):465-72.
    View in: PubMed
    Score: 0.017
  16. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophr Res. 2005 Dec 01; 80(1):1-8.
    View in: PubMed
    Score: 0.015
  17. Manschreck TC, Ames D. Neurologic features and psychopathology in schizophrenic disorders. Biol Psychiatry. 1984 May; 19(5):703-19.
    View in: PubMed
    Score: 0.014
  18. Manschreck TC, Maher BA, Rucklos ME, Vereen DR. Disturbed voluntary motor activity in schizophrenic disorder. Psychol Med. 1982 Feb; 12(1):73-84.
    View in: PubMed
    Score: 0.012
  19. Manschreck TC, Maher BA, Ader DN. Formal thought disorder, the type-token ratio and disturbed voluntary motor movement in schizophrenia. Br J Psychiatry. 1981 Jul; 139:7-15.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.